Value-based insurance significantly increased use of medications for secondary prevention among people with diabetes, according to a study. With value-based insurance design (VBID), copayments are lower for treatments deemed beneficial in the evidence-based literature. The study was conducted by Dr. Allison B. Rosen of the University of Michigan, Ann Arbor, and colleagues. EGMN's Damian McNamara interviews Dr. Rosen at the annual meeting of the Society of General Internal Medicine.
All Comments